Kingstad-Bakke B, Lee W, Yount Jr B, Cleven T, Park H, Sullivan J
Commun Biol. 2025; 8(1):392.
PMID: 40057586
PMC: 11890755.
DOI: 10.1038/s42003-025-07820-7.
Salo J, Marcelo L, Sanchez A, Marcelino C, Hazel Anne L, Miranda K
Acta Med Philipp. 2025; 59(2):72-80.
PMID: 39967711
PMC: 11831086.
DOI: 10.47895/amp.vi0.8188.
Kaneko T, Ezra S, Abdo R, Voss C, Zhong S, Liu X
Clin Proteomics. 2024; 21(1):13.
PMID: 38389037
PMC: 10882830.
DOI: 10.1186/s12014-024-09457-w.
Han W, Lee J, Chun J, Choi Y, Kim Y, Han M
Acute Crit Care. 2023; 38(1):41-48.
PMID: 36935533
PMC: 10030246.
DOI: 10.4266/acc.2022.01235.
Pessano Fialho M, Brum E, Oliveira S
Inflammopharmacology. 2023; 31(2):633-651.
PMID: 36849853
PMC: 9970139.
DOI: 10.1007/s10787-023-01160-w.
Correlation of Patient Profiles and Biomarkers with Outcomes in Covid-19 Icu Patients: A Retrospective Analysis.
Raman K, Kumar D, Kumar A, Saxena K, Kohli A, Wadhawan S
Rom J Anaesth Intensive Care. 2023; 28(2):71-79.
PMID: 36844114
PMC: 9949024.
DOI: 10.2478/rjaic-2021-0012.
Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality.
Santos J, Zanardi P, Alo V, Dos Santos V, Bovone L, Rodriguez M
J Clin Med. 2023; 12(4).
PMID: 36836076
PMC: 9966668.
DOI: 10.3390/jcm12041542.
[Should we interfere with the interleukin-6 receptor during COVID-19: What do we know?].
Lefevre C, Plocque A, Tran M, Creux M, Philippart F
Rev Mal Respir. 2022; 40(1):24-37.
PMID: 36577608
PMC: 9791331.
DOI: 10.1016/j.rmr.2022.11.085.
Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid.
Ahmad F
World J Crit Care Med. 2022; 11(4):228-235.
PMID: 36051943
PMC: 9305679.
DOI: 10.5492/wjccm.v11.i4.228.
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry.
Weiss D, Filiano A, Galipeau J, Khoury M, Krampera M, Lalu M
Cytotherapy. 2022; 24(11):1071-1073.
PMID: 36028438
PMC: 9339970.
DOI: 10.1016/j.jcyt.2022.07.010.
Tocilizumab and COVID-19: Timing of Administration and Efficacy.
Abidi E, El Nekidy W, Alefishat E, Rahman N, Petroianu G, El-Lababidi R
Front Pharmacol. 2022; 13:825749.
PMID: 35250575
PMC: 8894855.
DOI: 10.3389/fphar.2022.825749.
Single-cell immunology of SARS-CoV-2 infection.
Tian Y, Carpp L, Miller H, Zager M, Newell E, Gottardo R
Nat Biotechnol. 2021; 40(1):30-41.
PMID: 34931002
PMC: 9414121.
DOI: 10.1038/s41587-021-01131-y.
Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment.
Melegari G, Giuliani E, Dallai C, Veronesi L, Bertellini E, Osmenaj S
J Pers Med. 2021; 11(11).
PMID: 34834586
PMC: 8622280.
DOI: 10.3390/jpm11111234.
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D, Shono A, van Kalken C, van der Spek P, Krenning E, Kotani T
Purinergic Signal. 2021; 18(1):13-59.
PMID: 34757513
PMC: 8578920.
DOI: 10.1007/s11302-021-09814-6.
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion.
Mazzoni A, Salvati L, Maggi L, Annunziato F, Cosmi L
Semin Immunol. 2021; 55:101508.
PMID: 34728121
PMC: 8547971.
DOI: 10.1016/j.smim.2021.101508.
Lung Ultrasound in Patients With SARS-COV-2 Pneumonia: Correlations With Chest Computed Tomography, Respiratory Impairment, and Inflammatory Cascade.
Fratianni G, Malfatto G, Perger E, Facchetti L, Pini L, Bosco M
J Ultrasound Med. 2021; 41(6):1465-1473.
PMID: 34533859
PMC: 8662157.
DOI: 10.1002/jum.15831.
COVID-19 and the human innate immune system.
Schultze J, Aschenbrenner A
Cell. 2021; 184(7):1671-1692.
PMID: 33743212
PMC: 7885626.
DOI: 10.1016/j.cell.2021.02.029.
Case Report: Takotsubo Syndrome Associated With Novel Coronavirus Disease 2019.
Ortuno S, Jozwiak M, Mira J, Nguyen L
Front Cardiovasc Med. 2021; 8:614562.
PMID: 33693034
PMC: 7937625.
DOI: 10.3389/fcvm.2021.614562.
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients.
Phadke V, Scanlon N, Jordan S, Rouphael N
Curr Transplant Rep. 2021; 8(2):127-139.
PMID: 33688459
PMC: 7931983.
DOI: 10.1007/s40472-021-00322-5.
Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y, Mehta R, Kulkarni U, Karnik N, Gokhale S, Sundar U
BMC Infect Dis. 2021; 21(1):241.
PMID: 33673818
PMC: 7934984.
DOI: 10.1186/s12879-021-05912-3.
